- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.03. | Virax Biolabs faces Nasdaq minimum bid price noncompliance | 1 | Investing.com | ||
| 15.03. | Virax Biolabs receives Nasdaq notification letter regarding minimum bid price deficiency | 1 | Seeking Alpha | ||
| 15.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.03. | Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 277 | PR Newswire | LONDON, March 15, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and... ► Artikel lesen | |
| 22.01. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.01. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.12.23 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.12.23 | Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation | 109 | PR Newswire | LONDON, Dec. 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative diagnostics company focused on the detection of immune responses and diagnosis... ► Artikel lesen | |
| 08.12.23 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.12.23 | Virax Biolabs files for up to $30M mixed securities shelf | 1 | Seeking Alpha | ||
| 08.11.23 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.10.23 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASEP MEDICAL | 0,104 | -2,80 % | Asep Medical bestätigt, dass der Einsatz von KI verbesserte Behandlungen der häufigen Biofilminfektionen und eine schnelle Sepsisdiagnose ermöglicht | VANCOUVER, BC, 13. März 2024 - In seiner jüngsten Präsentation vor der US-amerikanischen Biophysical Society in Philadelphia1 berichtete Dr. Bob Hancock, CEO von Asep Medical Holdings... ► Artikel lesen | |
| GENPREX | 2,205 | +11,48 % | Genprex, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 4,110 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool | Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade... ► Artikel lesen | |
| GRITSTONE BIO | 0,663 | -3,91 % | Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of "Off-the-Shelf" Neoantigen Vaccine Platform (SLATE) | -- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 4,200 | -1,87 % | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies... ► Artikel lesen | |
| ANNOVIS BIO | 9,590 | +1,27 % | Annovis Bio Inc.: Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results | MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative... ► Artikel lesen | |
| HUMACYTE | 3,700 | +3,06 % | Here's why the Humacyte (HUMA) stock price is pumping | ||
| SAGIMET BIOSCIENCES | 4,040 | +6,88 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat | SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,900 | -1,69 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| QIAGEN | 37,470 | +1,19 % | Kursverluste für das Wertpapier von Qiagen NV (37,815 €) | An der Börse liegt der Anteilsschein von Qiagen NV gegenwärtig im Minus. Das Papier notiert derzeit bei 37,82 Euro. Ein Verlust von 0,79 Prozent steht gegenwärtig für das Wertpapier von Qiagen NV zu... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 9,100 | -3,70 % | Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts | ||
| RECURSION PHARMACEUTICALS | 7,350 | -0,68 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| EVOTEC | 13,260 | -1,41 % | DEUTSCHE BANK RESEARCH stuft Evotec auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Evotec von "Hold" auf "Buy" hochgestuft, das Kursziel aber von 20 auf 19 Euro gesenkt. Das Biotech-Unternehmen sollte 2024 eine positive Trendwende... ► Artikel lesen | |
| ADMA BIOLOGICS | 6,270 | +1,13 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 46,910 | -2,98 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,29 % bei einem Aktienkurs von 0,644 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
